Homocysteine and coronary atherosclerosis

Journal of the American College of Cardiology

Volumn 27, Issue 3, 1996, Pages 517-527

  Mayer, Ellen L ^a   Jacobsen, Donald W ^a   Robinson, Killian ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZARIBINE; CARBAMAZEPINE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; METHOTREXATE; NITROUS OXIDE; ORAL CONTRACEPTIVE AGENT; PENICILLAMINE; PHENYTOIN; PYRIDOXINE;

CORONARY ARTERY ATHEROSCLEROSIS; HUMAN; HYPERHOMOCYSTEINURIA; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0029878181     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(95)00508-0     Document Type: Review

References (127)

1. Munro HN, Crim M. The proteins and amino acids. In: Shils ME, Young VR, editors. Modern Nutrition in Health and Disease. 7th ed. Lea & Febiger, Philadelphia, 1988:30.
2. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990;1:228-37.
3. Finkelstein JD, Martin JJ. Methionine metabolism in mammals: adaptation to methionine excess. J Biol Chem 1986;261:1582-7.
4. Ueland PM, Refsum H, Brattström L. Plasma homocysteine and cardiovascular disease. In: Francis RB Jr, editor. Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function. New York: Marcel Dekker, 1992:183-236.
5. Christensen B, Refsum H, Vintermyr O, Ueland PM. Homocysteine export from cells cultured in the presence of physiological or superfluous levels of methionine: methionine loading of non-transformed, transformed, proliferating and quiescent cells in culture. J Cell Physiol 1991;146:52-62.
6. Refsum H, Christensen B, Djurhuus R, Ueland PM. Interaction between methotrexate, "rescue" agents and cell proliferation as modulators of homocysteine export from cells in culture. J Pharmacol Exp Ther 1991;258: 559-66.
7. Svardal AM, Djurhuus R, Refsum H, Ueland PM. Disposition of homocysteine in rat hepatocytes and in nontransformed and malignant mouse embryo fibroblasts following exposure to inhibitors of S-adenosylhomocysteine catabolism. Cancer Res 1986;46:5095-5100.
8. Mansoor MA, Svardal AM, Ueland PM. Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma. Anal Biochem 1992;200:218-29.
9. Refsum H, Helland S, Ueland PM. Radioenzymic determination of homocysteine in plasma and urine. Clin Chem 1985;31:624-8.
10. Malinow MR, Axthelm MK, Meredith MJ, MacDonald NA, Upson BM. Synthesis and transsulfuration of homocysteine in blood. J Lab Clin Med 1994;123:421-9.
11. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 1976;57:1079-82.
12. Boers GHJ, Smals AGH, Trijbels FJM, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313:709-15.
13. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
14. Murphy-Chutorian DR, Wexman MP, Grieco AJ, et al. Methionine intolerance: a possible risk factor for coronary artery disease. J Am Coll Cardiol 1985;6:725-30.
15. Kang S-S, Wong PWK, Cook HY, Norusis M, Messer JV. Protein-bound homocyst(e)ine. A possible risk factor for coronary artery disease. J Clin Invest 1986;77:1482-6.
16. Jacobsen DW, Gatautis VJ, Green R, et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem 1994;40:873-81.
17. Malinow MR, Kang SS, Taylor LM, et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989;79:1180-8.
18. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993;39:1764-79.
19. Israelsson B, Brattström LE, Hultberg BL. Homocysteine and myocardial infarction. Atherosclerosis 1988;71:227-33.
20. Genest JJ, McNamara JR, Upson B, et al. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler Thromb 1991;11:1129-36.
21. Ubbink JB, Vermaak WJH, Bennett JM, Becker PJ, van Staden DA, Bissbort S. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease. Klin Wochenschr 1991;69:527-34.
22. Brattström L, Lindgren A, Israelsson B, et al. Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest 1992;22:214-21.
23. Reed T, Malinow MR, Christian JC, Upson B. Estimates of heritability of plasma homocyst(e)ine levels in aging adult male twins. Clin Genet 1991;39:425-8.
24. Wilcken DEL, Reddy SG, Gupta VJ. Homocysteinemia, ischemic heart disease and the carrier state for homocystinuria. Metabolism 1983;32:363-70.
25. Williams RR, Malinow MR, Hunt SC, et al. Hyperhomocyst(e)inemia in Utah siblings with early coronary disease. Coron Artery Dis 1990;1:681-5.
26. Brattström L, Israelsson B, Norrving B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease: effects of pyridoxine and folic acid treatment. Atherosclerosis 1990; 81:51-60.
27. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.
28. 12 metabolism. Annu Rev Nutr 1987;7:291-320.
29. Fenton WA, Rosenberg LE. Inherited disorders of cobalamin transport and metabolism. In: The Metabolic and Molecular Basis of Inherited Disease. 7th ed. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. New York: McGraw Hill, 1995:3129-49.
30. Erbe RW. Inborn errors of folate metabolism. In: Blakely RL, Whitehead VM, editors. Folates and Pterins: Nutritional, pharmacological and physiological aspects. Wiley, New York, 1986:413-65.
31. Rosenblatt DS. Inherited disorders of folate transport and metabolism. In Ref. 29:3111-28.
32. Goyette P, Sumner JS, Milos R, et al. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet 1995;7:195-200.
33. Goyette P, Frosst P, Rosenblatt DS, Rozen R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am J Hum Genet 1995;56:1052-9.
34. Kang S-S, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991;48:536-45.
35. Kang S-S, Passen EL, Ruggie N, Wong PWK, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1993;88:1463-9.
36. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
37. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-8.
38. Andersson A, Brattström L, Israelsson B, Isaksson A, Hamfelt A, Hultberg B. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest 1992;22:79-87.
39. Nordström M, Kjellström T. Age dependency of cystathionine beta-synthase activity in human fibroblasts in homocyst(e)inemia and atherosclerotic vascular disease. Atherosclerosis 1992;94:213-21.
40. Boers GH, Smals AG, Trijbels FJ, Leermakers AI, Kloppenborg PW. Unique efficacy of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J Clin Invest 1983;72:1971-6.
41. Wu LL, Wu J, Hunt SC, et al. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem 1994;40:552-61.
42. Wilcken DEL, Gupta VJ. Sulfur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulfide. Eur J Clin Invest 1979;9:301-7.
43. Chauveau P, Bernadette C, Coudé M, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993;43: S72-7.
44. 12 deficiency than in heterozygosity for homocystinuria due to cystathionine β-synthase deficiency. Metabolism 1988;37: 175-8.
45. Kang S-S, Wong PWK, Norusis M. Homocysteinemia due to folate deficiency. Metabolism 1987;36:458-62.
46. Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Lindenbaum J. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest 1988;81:466-74.
47. Lindenbaum J, Rosenberg IH, Wilson PWF, Stabler S, Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 1994;60:2-11.
48. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993;57:47-53.
49. Pancharuniti N, Lewis CA, Sauberlich HE, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 1994;59:940-8.
50. Miller JW, Ribaya-Mercado JD, Russell RM, et al. Effect of vitamin B-6 deficiency on fasting plasma homocysteine concentrations. Am J Clin Nutr 1992;55:1154-60.
51. Refsum H, Wesenberg F, Ueland PM. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res 1991;51:828-35.
52. Wu JT, Wu L, Wilson W. Increased levels of plasma homocysteine in patients with various carcinomas [abstract]. Ir J Med Sci 1995;164:29A.
53. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease and drug therapy. J Lab Clin Med 1989;114:473-501.
54. Taylor LM Jr, DeFrang RD, Harris EJ Jr, Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg 1991;13:128-36.
55. Blankenhorn DH, Malinow R, Mack WJ. Colestipol plus niacin therapy elevates plasma homocyst(e)ine levels. Coron Art Dis 1991;2:357-60.
56. Wong PWK, Kang S-S. Accelerated atherosclerosis. Am J Med 1988;84: 1093-4.
57. van der Mooren MJ, Wouters MGAJ, Blom HJ, Schellekens LA, Eskes TKAB, Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994;24:733-6.
58. Gerritsen T, Vaughn JG, Waisman HA. The identification of homocystine in the urine. Biochem Biophys Res Commun 1962;9:493-6.
59. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet 1985;37:1-31.
60. Mudd SH, Levy HL, Skovby F. Disorders of transulfuration. In: Ref. 30:1279-327.
61. Dudman NPB, Hicks C, Lynch JF, Wilcken DEL, Wang J. Homocysteine thiolactone disposal by human arterial endothelial cells and serum in vitro. Arterioscler Thromb 1991;11:663-70.
62. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986;77: 1370-6.
63. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980;18:113-21.
64. Dudman NPB, Wilcken DEL Increased plasma copper in patients with homocystinuria due to cystathionine β-synthase deficiency. Clin Chim Acta 1983;127:105-13.
65. Oster O, Dahm M, Oelert H, Prellwitz W. Concentrations of some trace elements (Se, Zn, Cu, Fe, Mg, K) in blood and heart tissue of patients with coronary heart disease. Clin Chem 1989;35:851-6.
66. Panganamala RV, Karpen CW, Merola AJ. Peroxide mediated effects of homocysteine on arterial prostacyclin synthesis. Prostaglandins Leukotrienes Med 1986;22:349-56.
67. Wang J, Dudman NPB, Wilcken DEL. Effects of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelial cells. Thromb Haemostas 1993;70:1047-52.
68. Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308-18.
69. Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994;91:6369-73.
70. Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med 1974;291:537-43.
71. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976;58:731-41.
72. Harker LA, Harlan JM, Ross R. Effects of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circ Res 1983;53:731-9.
73. Reddy GSR, Wilcken DEL. Experimental homocysteinemia in pigs: comparison with studies in sixteen homocystinuric patients. Metabolism 1982; 31:778-83.
74. 6: relationship to atherosclerosis. J Nutr 1983;113:2122-33.
75. Donahue S, Sturman JA, Gaull G. Arteriosclerosis due to homocyst(e)inemia: failure to reproduce the model in weaning rabbits. Am J Pathol 1974;77:167-74.
76. McCully KS, Ragsdale BD. Production of arteriosclerosis by homocysteinemia. Am J Pathol 1970;61:1-8.
77. Rinehart JF, Greenberg LD. Arteriosclerotic lesions in pyridoxine-deficient monkeys. Am J Pathol 1949;25:481-91.
78. Krishnaswamy K, Rao SB. Failure to produce atherosclerosis in Macaca radiata on a high-methionine, high-fat, pyridoxine-deficient diet. Atherosclerosis 1977;27:253-8.
79. Rolland PH, Friggi A, Barlatier A, et al. Hyperhomocysteinemia induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation 1995;91:1161-74.
80. Celermajer DS, Sorensen K, Ryalls M, et al. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol 1993;22:854-8.
81. Uhlemann ER, TenPas JH, Lucky AW, Schulman JD, Mudd SH, Shulman NR. Platelet survival and morphology in homocystinuria due to cystathionine synthase deficiency. N Engl J Med 1976;295:1283-6.
82. 111indium-labeled platelets in patients with homocystinuria. N Engl J Med 1982;307:781-6.
83. McDonald L, Bray C, Field C, Love F, Davies B. Homocystinuria, thrombosis and the blood-platelets. Lancet 1964;1:745-6.
84. Hilden M, Brandt NJ, Nilsson IM, Schonheyder F. Investigation of coagulation and fibrinolysis in homocystinuria. Acta Med Scand 1974;195: 533-5.
85. Graeber JE, Slott JH, Ulane RE, Schulman JD, Stuart M. Effect of homocysteine and homocystine on platelet and vascular arachidonic acid metabolism. Pediatr Res 1982;16:490-3.
86. Di Minno G, Daví G, Margaglione M, et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest 1993;92:1400-6.
87. Giannini MJ, Coleman M, Innerfield I. Antithrombin activity in homocystinuria [letter]. Lancet 1975;1:1094.
88. Palareti G, Coccheri S. Lowered antithrombin III activity and other clotting changes in homocystinuria: effects of a pyridoxine-folate regimen. Haemostasis 1989;19 Suppl:24-8.
89. Rosenberg RD. Actions and interactions of antithrombin and heparin. N Engl J Med 1975;292:146-51.
90. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986;77: 1909-16.
91. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990;75:895-901.
92. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991;88:1906-14.
93. Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992;79: 2930-6.
94. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993;92:1381-6.
95. Lentz SR, Sadler JE. Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood 1993;81:683-9.
96. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993;91:2873-9.
97. von Eckardstein A, Malinow MR, Upson B. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb 1994;14:960-4.
98. Araki A, Sako Y, Fukushima Y, Matsumoto M, Asada T, Kita T. Plasma sulfhydryl-containing amino acids in patients with cerebral infarction and in hypertensive patients. Atherosclerosis 1989;79:139-46.
99. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990;21:572-6.
100. Brattström LE, Hardebo JE, Hultberg BL. Moderate homocysteinemia - a possible risk factor for arteriosclerotic cerebrovascular disease. Stroke 1984;15:1012-6.
101. Mölgaard J, Malinow MR, Lassvik C, Holm A-C, Upson B, Olsson AG. Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication. J Intern Med 1992;231:273-9.
102. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disese. Int J Epidemiol 1995;24:704-9.
103. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-81.
104. Dudman NPB, Wilcken DEL, Wang J, Lynch JF, Macey D, Lundberg P. Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology. Arterioscler Thromb 1993;13:1253-60.
105. Graham IM. Homocysteinaemia and vascular disease. In: Vuylsteek K, Hallen M, editors. Epidemiology. Luxembourg: Commission of the European Community, Ios Press. 1994:332-53.
106. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. N Engl J Med 1995;332:286-91.
107. Robinson K, editor. Homocysteinaemia and Vascular Disease. Luxembourg: Commission of the European Communities, 1990.
108. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994;106:9-19.
109. Robinson K, Mayer EL, Miller DP, et al. Hyperhomocysteinemia and low pyridoxal phosphate: independent and reversible risk factors for coronary artery disease. Circulation 1995;92:2825-30.
110. Glueck CJ, Shaw P, Lang J, Tracy T, Seive-Smith L, Wang Y. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 1995;75:132-6.
111. Bergmark C, Mansoor MA, Swedenborg J, de Faire U, Svardal AM, Ueland PM. Hyperhomocysteinemia in patients operated for lower extremity ischaemia below the age of 50 - effect of smoking and extent of disease. Eur J Vasc Surg 1993;7:391-6.
112. Heinecke JW, Kawamura M, Suzuki L, Chait A. Oxidation of low density lipoprotein by thiols: superoxide-dependent and -independent mechanisms. J Lipid Res 1993;34:2051-61.
113. Parthasarathy S. Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor. Biochim Biophys Acta 1987;917:337-40.
114. Brattström LE, Israelsson B, Jeppson J-O, Hultberg BL. Folic acid - an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988;48:215-21.
115. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ, Delport R, Potgeiter HC. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994;124:1927-33.
116. Wilcken DEL, Gupta VJ, Betts AK. Homocysteine in the plasma of renal transplant recipients: effects of cofactors for methionine metabolism. Clin Sci 1981;61:743-9.
117. Brattström L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med 1994;236:633-41.
118. Franken DG, Boers GHJ, Blom HJ, Trijbels FJM, Kloppenborg PWC. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb 1994;14:465-70.
119. 6 and folate reduce homocysteine concentrations in coronary artery disease [abstract]. Ir J Med Sci 1993;162:197A.
120. Saltzman E, Mason JB, Jacques PF, et al. B vitamin supplementation lowers homocysteine levels in heart disease [abstract]. Clin Res 1994;42:172A.
121. Landgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A, Brattström L. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Intern Med 1995;237:381-8.
122. 6 supplements in elderly people with normal serum vitamin concentrations. Lancet 1995;346:85-9.
123. McMartin KE, Phifer TJ, Alexander JS, Middlebrooks M, Childress LE. Homocysteine and iron interactions in endothelial cells:role in atherosclerosis. Ir J Med Sci 1995;164:14.
124. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The atherosclerosis risk in communities study. Circulation 1993;87: 1107-13.
125. Mayer EL, Robinson K, Jacobsen DW, et al. Low plasma homocysteine levels predict reduced atheroma burden in patients undergoing coronary interventions: evidence from intravascular ultrasound [abstract]. J Am Coll Cardiol 1995;25:81A.
126. Ambrosi P, Barlatier A, Habib G, et al. Hyperhomocysteinaemia in heart transplant recipients. Eur Heart J 1994;15:1191-5.
127. Berger PB, Jones JD, Olson LJ, et al. Increase in total plasma homocysteine concentration after cardiac transplantation. Mayo Clin Proc 1995;70: 125-31.